Enterprise AI Analysis
Correlation between human expert macular fluid height assessment and fluid volume quantification in neovascular age-related macular degeneration
Stefan Steiner, Bianca S. Gerendas, Gabor Deak, Oliver Leingang, Ariadne Whitby, Hrvoje Bogunovic, Gregor S. Reiter & Ursula Schmidt-Erfurth
This study evaluates the critical role of AI in ophthalmic diagnostics, specifically for neovascular age-related macular degeneration (nAMD). By comparing manual expert assessment of macular fluid height with automated AI-quantification, we uncover how AI can provide a more comprehensive and reliable measure of disease activity, moving beyond traditional, limited B-scan measurements.
Executive Impact: Precision in Ophthalmic AI
Automated AI solutions offer unprecedented precision and efficiency in managing neovascular Age-related Macular Degeneration (nAMD), significantly enhancing diagnostic capabilities and patient care beyond traditional manual methods.
0.91
Strongest AI-Human Agreement (PED Fluid Height)
536
Total Eyes with AI-Detected IRF (Overall Cohort)
78%
Max SRF Fluid Heights Found Outside CMM
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Methodology & AI Integration
Quantitative Findings
Clinical Implications
Enterprise Process Flow: Automated Fluid Assessment
OCT Volume Acquisition
→
AI Segmentation (RetInSight Fluid Monitor)
→
3D Fluid Volume Quantification
→
Max Vertical Fluid Extent Calculation
→
Spatial Localization Mapping
→
Automated Disease Activity Measure
| Feature | Manual Assessment | AI-based Quantification |
|---|---|---|
| Method |
|
|
| Speed |
|
|
| Scope |
|
|
| Accuracy (IRF/PED) |
|
|
| Accuracy (SRF) |
|
|
| Disease Activity |
|
|
0.91
Highest Correlation (PED) between AI and Manual Fluid Height
AI-based and manual fluid height measurements showed strong agreement, particularly for Pigment Epithelial Detachment (PED), indicating high reliability in this critical diagnostic parameter.
6mm
Critical Macular Area for Total Fluid Volume Assessment
Manual Central Millimeter (CMM) height poorly correlated with total fluid volumes in the central 6mm, underscoring the need for whole-volume assessment to capture full disease activity.
Enhancing nAMD Management with AI
Real-world impact of comprehensive AI-driven fluid monitoring.
A major challenge in nAMD treatment is the subjective and time-consuming nature of manual fluid assessment. By enabling rapid and precise quantification of fluid volumes and their spatial distribution across retinal layers, AI transforms clinical practice. This leads to more accurate measures of disease activity, supports personalized anti-VEGF treatment regimens, and can potentially improve long-term visual outcomes. The ability to identify fluid distribution beyond the central millimeter addresses a significant limitation of traditional methods like Central Retinal Thickness (CRT), allowing ophthalmologists to detect and monitor exudation more effectively across the entire macula.
Calculate Your AI Implementation ROI
Estimate the potential time savings and cost efficiencies your organization could achieve by integrating AI-powered ophthalmic diagnostics.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A clear, phased approach to integrating AI into your ophthalmic practice, ensuring a smooth transition and maximum impact.
Phase 1: Data Integration & AI Model Deployment
Establish secure data pipelines from your OCT systems, ensuring seamless integration with the RetInSight Fluid Monitor. Deploy the validated AI model within your existing IT infrastructure, focusing on data privacy and security compliance.
Phase 2: Clinician Training & Workflow Integration
Conduct comprehensive training for ophthalmologists and support staff on using the AI interface and interpreting its outputs. Integrate AI-powered fluid assessment into your standard diagnostic and treatment planning workflows, optimizing for efficiency.
Phase 3: Performance Monitoring & Iterative Refinement
Implement continuous monitoring of AI model performance and accuracy, collecting clinician feedback. Utilize this data for iterative refinement and updates to the AI model, ensuring it adapts to evolving clinical needs and new research.
Phase 4: Scaling & Advanced Analytics Adoption
Expand AI deployment to wider patient cohorts and additional clinics. Explore integration with advanced analytics, such as predictive models for treatment response or personalized dosage regimens, to further enhance patient outcomes.
Unlock the Full Potential of AI in Ophthalmic Diagnostics
Ready to revolutionize your practice with accurate, efficient, and comprehensive fluid assessment for nAMD? Our experts are here to guide you.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat